The accelerated approval of Sarepta Therapeutics Inc.'s (Nasdaq: SRPT) eteplirsen raised expectations for a swift approval of PTC Therapeutics Inc.'s (Nasdaq: PTCT) nonsense mutation Duchenne muscular dystrophy treatment Translarna. Shares of Sarepta leaped $20.79 to close at $48.94 while PTC Therapeutics stock climbed $1.88 to close at $10.99.
Swift approval expected for PTC Therapeutics' Translama
September 19, 2016 at 19:09 PM EDT